Cell and Gene Therapy: Transforming Treatment Paradigms for Patient‐Centric Care
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70430 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Sojeong Yi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Alnylam Pharmaceuticals, Inc, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Patient-Centered Care, Cell- and Tissue-Based Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Cell and gene therapies (CGTs) are transforming medicine by offering potential cures for diseases previously considered untreatable. Despite rapid advancements, challenges remain in optimizing efficacy and safety and ensuring patient accessibility and preference due to high costs and clinical uncertainties, particularly for rare diseases and one‐time administration. The American Society of Clinical Pharmacology & Therapeutics (ASCPT) held a CGT satellite conference in 2025, titled “Cell and Gene Therapy: Transforming Treatment Paradigms for Patient‐Centric Care.” This manuscript summarizes the conference, covering gene therapies and T‐cell immunotherapies from scientific, clinical, and patient‐centered perspectives. Key topics on gene therapy included “platformization” to streamline development, lessons from adeno‐associated virus‐based gene therapies for hemophilia from patient and clinical perspectives, clinical pharmacology, and model‐informed drug development (MIDD) considerations. The conference also highlighted T‐cell immunotherapies including chimeric antigen receptor T therapy (CAR T), focusing on factors affecting cellular kinetics, efficacy, and safety, as well as emerging allogeneic CAR T for autoimmune diseases and MIDD strategies to optimize therapy design and clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Alnylam Pharmaceuticals, Inc, Cambridge, Massachusetts, USA.
- Lima Hui BioConsulting, Seattle, Washington, USA.
- Pfizer, Inc, Collegeville, Pennsylvania, USA.
- National Bleeding Disorders Foundation, New York, New York, USA.
- Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA.
- Third Arc Bio, Inc, Lower Gwynedd, Pennsylvania, USA.
ORCID-Profile: Sojeong Yi, Avery McIntosh, Maria E Santaella, Michael Z Liao
Zitieren
APA
Yi, S., Wu, C. Y., McIntosh, A., Santaella, M. E., Robinson, T. M., & Liao, M. Z. (2025). Cell and Gene Therapy: Transforming Treatment Paradigms for Patient‐Centric Care. Clinical and Translational Science. https://doi.org/10.1111/cts.70430
Vancouver
Yi S, Wu CY, McIntosh A, Santaella ME, Robinson TM, Liao MZ. Cell and Gene Therapy: Transforming Treatment Paradigms for Patient‐Centric Care. Clinical and Translational Science. 2025. doi:10.1111/cts.70430
BibTeX
@article{Yi2025,
author = {Yi, Sojeong and Wu, Chia-Yung and McIntosh, Avery and Santaella, Maria E and Robinson, Tara M and Liao, Michael Z},
title = {Cell and Gene Therapy: Transforming Treatment Paradigms for Patient‐Centric Care},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70430}
}
EUVIMED